Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) EPS (Basic) (2019 - 2025)

Harmony Biosciences Holdings' EPS (Basic) history spans 7 years, with the latest figure at $0.4 for Q4 2025.

  • For Q4 2025, EPS (Basic) fell 54.02% year-over-year to $0.4; the TTM value through Dec 2025 reached $2.76, up 7.81%, while the annual FY2025 figure was $2.76, 7.81% up from the prior year.
  • EPS (Basic) for Q4 2025 was $0.4 at Harmony Biosciences Holdings, down from $0.88 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $1.48 in Q3 2022 and bottomed at -$0.17 in Q3 2021.
  • The 5-year median for EPS (Basic) is $0.53 (2023), against an average of $0.56.
  • The largest annual shift saw EPS (Basic) tumbled 76.65% in 2021 before it surged 970.59% in 2022.
  • A 5-year view of EPS (Basic) shows it stood at $0.39 in 2021, then surged by 110.26% to $0.82 in 2022, then crashed by 43.9% to $0.46 in 2023, then skyrocketed by 89.13% to $0.87 in 2024, then tumbled by 54.02% to $0.4 in 2025.
  • Per Business Quant, the three most recent readings for HRMY's EPS (Basic) are $0.4 (Q4 2025), $0.88 (Q3 2025), and $0.69 (Q2 2025).